Meetings 

EvaluatePharma®, leader in life science sector analysis, delivers exclusive commercial intelligence and analysis into industry performance globally.

With 10+ years’ experience and investment in our services, we provide meaningful, value-added information and analysis that aids in target identification, strategic decision-making, and risk mitigation aimed towards your competitive advantage and business results.

Our flexible, “one-stop” services include:
EvaluatePharma® featuring all the Deals Data you need for Business Development, Proprietary Data Standardization, Merge Company tool, Calendar of Events, Interactive NPV Analyzer, Sales by Indication and Consensus Forecasts for Marketed & Pipeline Products, plus much more to give you the most accurate view of the global market.

EP Clinical Trials simplifies complex analysis of the global clinical trials landscape including ClinicalTrials.gov, EudraCT and Japan clinical trials data source for trusted clinical intelligence you can rely on, and the time savings you need.

EvaluatePharma® Partnering Services make finding your next licensing partner easier, and features the latest assets available for partnering presented in their commercial context alongside our unique industry analysis.

EPVantage® renowned news service provides mapped commentary and analysis that keeps you abreast of the latest sector developments relevant to you.

Discover why EvaluatePharma is trusted and relied upon by life science companies big and small, the investment community and leading consultancies.

You can count on EvaluatePharma for:

• Product Forecasts to 2018
• New – Sales by Indication to 2018
• Product Deals
• M&A Transactions
• Product Historic Sales
• Clinical Trials
• Country Analysis
• Archived Historical Sales Forecasts
• Company profiles
• Drug Information
• R&D Pipelines
• Patent Risk
• News
• NPV’s of Marketed and Pipeline Products
• Calendar of Events - key events that will shape the future of the industry
• EP Vantage & Event Analyzer - analysis and commentary on key market events

Foley Hoag is a preeminent Life Sciences law firm that represents public and private clients in a wide range of transactions worldwide.  The chair of our Licensing and Strategic Alliances practice group together with one of our leading Intellectual Property partners will be available to meet with interested companies.

Fujifilm Diosynth is a leading provider of process development and cGMP manufacturing services for biopharmaceuticals. Fujifilm Diosynth offers a proven track record in process development and cGMP manufacturing of cell culture and microbial expressed proteins, vaccines, and monoclonal antibodies. The organization has facilities in Research Triangle Park, North Carolina, USA (formerly Diosynth Biotechnology) and Billingham, UK (formerly Avecia Biologics) and was acquired by Fujifilm Corporation in April 2011.  Combined, Fujifilm Diosynth brings to our clients over 25 years of experiences as a contract manufacturing organization. 

Created in 1981, Galderma is a joint venture between Nestlé and L'Oréal.

Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma’s important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, over-the-counter drugs and aesthetic and corrective solutions) contribute to maintaining its strong leadership in dermatology.

Galderma is interested in acquiring or in-licensing products for corrective dermatology and for the treatment of acne, rosacea, onychomycosis, psoriasis, seborrheic dermatitis, atopic dermatitis, other inflammatory dermatoses, non-melanoma skin cancer, viral warts, and pigmentary disorders.

GLG Research partners with organizations seeking efficient, targeted connections to insight.

Our Healthcare Practice provides you with access to expert insights on issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors. GLG works with:

• 9 of the top 10 pharmaceutical and biotechnology companies
• More than 80,000 experts from across the entire healthcare industry including physicians, researchers, scientists, payors, and healthcare industry executives
• 7 out of the top 10 global medical equipment companies
• Over 300,000 experts from all sectors, including former C-level operating executives, ex-top-tier strategy consultants and thought leaders from around the world

GfK Bridgehead is a global strategic healthcare consultancy that specializes in pricing and reimbursement, opportunity assessment, market access strategy, health economics, transaction support, valuation and due diligence.

Preferred partner for many major companies in the pharmaceutical, medical device, diagnostic and financial sectors.

Respected for bringing payer insights into R&D, portfolio, business development, commercialization and lifecycle strategies.

Renowned for qualitative and quantitative research capabilties.

A truly global organization, able to draw upon the expertise of 500 healthcare experts in more than 100 countries.

HealthCare Royalty Partners is a global healthcare investment firm with $1.5 billion in assets under management. Launched in 2007 by Founding Managing Directors Gregory B. Brown, M.D., Todd C. Davis and Clarke B. Futch, HC Royalty specializes in making structured investments in commercial-stage healthcare companies and products. Our deep experience, broad and flexible investment platform and proven track record set HC Royalty apart from other firms.

We closed on our first fund, HealthCare Royalty Partners, L.P., in July 2008 with over $500 million in capital. At closing this represented one of the largest inaugural healthcare-focused funds ever raised. In December 2011, we closed the largest private equity fund dedicated to healthcare royalty investments, HealthCare Royalty Partners II, L.P. and an affiliated fund, with $1 billion in capital. Our world-class list of investors consists of public and corporate pension funds, financial institutions, insurance companies, funds-of-funds and university endowments.

Our broad-based internal team has deep investment skills, as well as financial, legal and operational expertise. Collectively, these individuals possess over 100 years of healthcare and financial experience specifically in principal investing, structured finance, healthcare industry senior management, Wall Street research, healthcare industry consulting, and scientific and clinical advisory work

Founded in 2007, HealthCare Royalty Partners is a global healthcare investment firm with over USD 1.5 billion of capital under management. The Firm specializes in structured financing solutions for the life sciences industry.